Cite
HARVARD Citation
Ye, H. et al. (n.d.). The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma. Current eye research. pp. 1507-1512. [Online].